

1 **The power behind the throne; senescence and the hallmarks of cancer**

2

3 Matthew Hoare^{1,2*}, and Masashi Narita^{1,*}

4

5 ¹University of Cambridge, Cancer Research UK Cambridge Centre, Robinson
6 Way, Cambridge, CB2 0RE, UK.

7 ²University of Cambridge, Department of Medicine, Addenbrooke's Hospital,
8 Cambridge, CB2 0QQ, UK.

9 *Correspondence: Matthew.Hoare@cruk.cam.ac.uk,

10 masashi.narita@cruk.cam.ac.uk

11

12

13 Key words:

14 Hallmarks, cancer, senescence, microenvironment, tumor suppressor

1 **Abstract**

2 The hallmarks of cancer was an attempt to describe the underlying principles
3 of carcinogenesis. In their latest iteration, there is a particular focus on the
4 role that the microenvironment and signalling between cancer cells and their
5 neighbors play in the pathology of tumors. Since the original description of the
6 hallmarks there has been a huge leap forward in our understanding of the
7 biology of cellular senescence promoting it from an autonomous tumor
8 suppressor to a complex, dynamic phenotype that can sometimes be tumor
9 suppressive, but sometimes oncogenic. In particular, our understanding of the
10 diverse non-autonomous effects that senescent cells can have upon both
11 cancer cells and the tumor microenvironment suggests that senescent cells
12 could play a major role in many human cancer types. Here we suggest that
13 cellular senescence could underpin the biology of many of the hallmarks of
14 cancer, making it the true power behind the throne.

1 **1. INTRODUCTION**

2 At the turn of the millennium Hanahan and Weinburg described their
3 hallmarks of cancer to try and distill the essential underlying changes that
4 cells undergo to develop into cancer (Hanahan & Weinberg 2000). This was
5 an attempt to reduce the vast complexity described in various types and
6 stages of cancer into its six underlying principles. One of these characteristics
7 was the insensitivity to anti-growth signals or the loss of tumor suppressor
8 function; their examples centered on the role of the retinoblastoma protein
9 (RB) and TGF- β as archetypes of autonomous and secreted cytostatic
10 factors, respectively. In the report, the description of senescence amounted to
11 a single reference to the recent identification that unrestricted expression of
12 oncogenic RAS could drive senescence (Serrano et al. 1997). At the time
13 cellular senescence was seen solely as an autonomous tumor suppressor
14 mechanism, but little was known of its role throughout the life-cycle and its
15 complex non-autonomous signalling.

16

17 Over the intervening time period the hallmarks of cancer have been updated
18 to include two additional hallmarks and two enabling characteristics with
19 particular focus on the tissue microenvironment. Importantly, over the same
20 time period there has been a recognition of the ubiquity of senescence in
21 human diseases and in pre-malignant lesions in particular (Collado & Serrano
22 2010, Collado et al. 2005). As a tumor suppressor mechanism found in the
23 earliest stages of cancer, senescence is positioned as a master controller of
24 premalignant cells and their ultimate fate to be cleared, remain static, or
25 progress. In addition, senescence has been described in multiple

1 physiological contexts such as embryological development (Muñoz-Espín et
2 al. 2013, Storer et al. 2013), wound healing (Demaria et al. 2014, Jun & Lau
3 2010) and normal aging (Burd et al. 2013).

4

5 Since the publication of the original hallmarks, it has been the explosion of our
6 understanding of the ability of senescent cells to co-ordinate other players
7 within the tumor microenvironment through secreted signals or cell-contact
8 that suggest that senescence rather than simply being an autonomous tumor
9 suppressor could underpin many of these hallmarks of cancer. Here we take
10 advantage of the hallmarks of cancer (highlighted in '**bold**' in the text) to
11 discuss the role of senescence in the development and progression of cancer,
12 in addition to the therapeutic opportunities that senescence presents to treat
13 both cancer and the side-effects of anti-cancer therapies.

14

15 **2. SENESENCE AS AN AUTONOMOUS TUMOR SUPPRESSOR**

16 **2.1. Replicative Senescence**

17 As '**replicative immortality and sustained proliferative signalling**' are
18 hallmarks of cancer, the converse, stable proliferative arrest, is the essential
19 hallmark of senescence. Senescence was first defined in cultured human
20 diploid fibroblasts (HDFs), as a state of 'irreversible cell cycle arrest' caused
21 by replicative exhaustion: after a certain number of replications, normal HDFs
22 lose their proliferative capacity, exhibiting morphological (e.g. enlarged cell
23 body and nuclei) and biochemical (e.g. accumulation of senescence-
24 associated β -galactosidase activity, SA β -GAL) alterations, called replicative
25 senescence (HAYFLICK 1965, Salama et al. 2014, Shay & Wright 2000). The

1 molecular correlate of ‘replicative exhaustion’ was found to be critically short
2 telomeres (Harley et al. 1990). Somatic cells in humans lack telomerase
3 activity, the enzyme responsible for telomeric elongation and each round of
4 mitosis causes telomeric attrition; critically short telomeres trigger a DNA
5 damage response (DDR) (Herbig et al. 2004). Thus, the cancer hallmark
6 **‘replicative immortality’** is a state of escape from replicative senescence.
7 Indeed, it has been shown that short telomeres in mice can limit
8 tumorigenesis through induction of senescence (Collado et al. 2007, Cosme-
9 Blanco et al. 2007, Feldser & Greider 2007), although it also causes genomic
10 instability, leading to a modest increase in spontaneous tumor formation in
11 highly proliferative cell types (Rudolph et al. 1999). Consistently, most
12 cancers cells aberrantly express telomerase to achieve this state (Kim et al.
13 1994, Shay & Wright 2011).

14

15 **2.2. Oncogene-induced senescence (OIS)**

16 It was also shown that various types of cytotoxic stress could induce a similar
17 phenotype, collectively termed premature senescence. Principally,
18 identification of OIS, first in culture (Serrano et al. 1997) and later in vivo
19 (Braig et al. 2005, Chen et al. 2005, Collado et al. 2005, Lazzerini Denchi et
20 al. 2005, Michaloglou et al. 2005), substantiated the role for senescence as a
21 tumor suppressor.

22

23 Initially, ectopic expression of constitutively active H-RAS (Serrano et al.
24 1997) and downstream effectors, MEK (Lin et al. 1998) or RAF1 (Zhu et al.
25 1998), were shown to paradoxically induce a senescence-like phenotype in

1 culture. Thus, supra-physiological mitogenic signalling somehow triggers anti-
2 proliferative effectors to avoid transformation. However, this process is liable
3 to bypass in certain situations: when these mitogenic oncogenes are co-
4 expressed with C-MYC or adenoviral E1A, cells fail to undergo senescence
5 and leads to immortalization with increased sensitivity to apoptosis. (Serrano
6 et al. 1997, Zhuang et al. 2008). Indeed, loss of c-MYC expression can lead to
7 a form of senescence (Wu et al. 2007). Considering that senescent cells are
8 typically resistant to apoptosis, these observations support the idea that
9 apoptosis and senescence back up each other for tumor suppression (Narita
10 & Lowe 2005).

11

12 In a series of studies, oncogene- or loss of tumor suppressor-induced
13 senescence have been identified in various tissues (Braig et al. 2005, Chen et
14 al. 2005, Collado et al. 2005, Lazzarini Denchi et al. 2005, Michaloglou et al.
15 2005), as exemplified by melanocytic naevi. The majority of human naevi
16 (~80%) carry the oncogenic *BRAF*^{V600E} mutation, as frequently as seen in
17 malignant melanoma; it is rare that naevi subsequently progress to
18 melanoma, suggesting that constitutive activation of BRAF is not sufficient for
19 melanomagenesis (Pollock et al. 2003). Melanocytes from excised human
20 naevi are largely non-proliferative and show multiple markers of senescence
21 including expression of p16 and SA β -GAL (Gray-Schopfer et al. 2006,
22 Michaloglou et al. 2005).

23

24 **2.3. Therapy-induced senescence (TIS)**

1 In addition to its tumor suppressive role, senescence is also a potential
2 therapeutic goal in fully developed cancer, termed therapy-induced
3 senescence (TIS). The first genetic evidence for in vivo TIS precedes that of
4 the OIS studies: In murine models of lymphoma, when apoptosis is defective,
5 chemotherapy leads to the accumulation of cells with a p53-dependent
6 senescent phenotype (Braig et al. 2005, Schmitt et al. 2002). Interestingly, in
7 the *E μ -myc* mouse lymphoma model, tumors in a p53-null background
8 regress after chemotherapy, whereas *E μ -myc* lymphomas with ectopic *Bcl2*
9 (apoptosis defective) show no tumor regression. Nevertheless, prognosis of
10 the latter is much better than the former (Schmitt et al. 2002). Post-treatment
11 the *E μ -myc-Bcl2* lymphoma cells exhibit a senescent phenotype, suggesting
12 that a non-apoptotic function of p53 (likely to be senescence) contributes to
13 the efficacy of the therapy (Schmitt et al. 2002). A TIS-like phenotype was
14 also identified in human breast cancer isolated from patients after neo-
15 adjuvant therapy (Poele et al. 2002). Following these initial studies, a number
16 of mouse models have been used to show TIS, some of which are
17 summarized elsewhere (Pérez-Mancera et al. 2014).

18

19 **2.4. The senescence network**

20 It is well recognized that underpinning the senescence response are two
21 critical tumor suppressor pathways that mediate inhibition of the cell cycle, in
22 addition to numerous other functions: the p53 (Brugarolas et al. 1995, Serrano
23 et al. 1997) and p16/RB pathways (See Fig. 1a & sidebar) (Alcorta et al. 1996,
24 Shay et al. 1991). However, increasing evidence suggest that it might be
25 more appropriate to view senescence as a combinatorial phenotype of diverse

1 effector programs, which can confer sub-phenotypes, forming a high-order
2 'pathway network' (Fig. 1b) (Salama et al. 2014). This is in marked contrast to
3 apoptosis, which could be seen as a single entity with clearly defined
4 pathway(s) (Czabotar et al. 2014).

5

6 There is significant cross-talk and co-operativity between p16/RB and p53
7 pathways: both p16 and the canonical p53 target, p21 are endogenous CDK
8 inhibitors, which activate RB to repress cell cycle genes, among others. P16 is
9 in particular has been rather specifically associated with senescence, making
10 it a robust maker of senescence. In contrast, p53 is involved in wider stress
11 responsive contexts, including cell cycle, acute DDR and DNA repair,
12 apoptosis, and metabolism (Levine & Oren 2009). Interestingly, it has recently
13 been shown that chronic activation of p53, such as seen in senescence,
14 drives a distinct transcriptional program to that seen in the acute p53
15 activation, upon DDR (see sidebar) (Kirschner et al. 2015). In addition, p53
16 has a range of different functions within the senescence context (Johmura &
17 Nakanishi 2016, Rufini et al. 2013). However, the relationship between p53
18 and other senescence effectors is not necessary linear: for example, p53
19 promotes the autonomous aspects of senescence, but as we discuss later,
20 p53 represses the senescence-associated secretory phenotype (SASP) that
21 underpins much of the functionality of the senescent cell (Lujambio et al.
22 2013, Rodier et al. 2009). In addition, it remains to be elucidated how these
23 two pathways interact within the complex senescence effector network.

24

25 **2.5. Stable Exit From Cell Cycle**

1 Senescence is distinct from quiescence in terms of the ‘irreversible’ nature of
2 the proliferative arrest. How is the stability of senescence arrest achieved?
3 This is particularly critical for OIS, which has constitutively ‘**sustained**
4 **proliferative signalling**’. A number of autonomous effectors potentially
5 contribute to this arrest (Fig. 1b). It has been shown that mutations causing
6 persistent activation of the RAS pathway provoke a negative feedback
7 response, which inhibits RAS/PI3K pathway in human cells at various levels in
8 the pathway (Courtois-Cox et al. 2006). A similar negative feedback was also
9 observed in the BRAF/MAPK pathway during the BRAF-induced melanocyte
10 senescence (Wajapeyee et al. 2008). This negative feedback was reported to
11 be mediated by secreted protein IGFBP7, although its involvement in OIS
12 might be dependent on cell type or experimental model studied (Scurr et al.
13 2010, Vizioli et al. 2011, Wajapeyee et al. 2008, 2010). It is also apparent that
14 other SASP components can reinforce the irreversibility of the senescence
15 arrest (Acosta et al. 2008, Kortlever et al. 2006, Kuilman et al. 2008).

16

17 Another plausible mechanism is ‘persistent’ DDR (pDDR) accompanied by
18 chronic activation of the p53 pathway (Fumagalli et al. 2014), as highlighted in
19 the case of telomere dysfunction. This can be caused, not only by replicative
20 stress (d’Adda di Fagagna et al. 2003, Herbig et al. 2004) but also by
21 inhibition of TRF2, a double-stranded telomeric DNA-binding protein essential
22 for telomere protection (Karlseder et al. 2002, Takai et al. 2003, van Steensel
23 et al. 1998). Paradoxically, the protective role for TRF2 at chromosomal ends
24 also appears to contribute to triggering pDDR. It has been suggested that the
25 activity of TRF2 prevents aberrant chromosomal fusions, partly by serving as

1 an endogenous inhibitor of DNA repair (Bae & Baumann 2007). Thus, DNA
2 damage in telomere regions is essentially irreparable and during senescence
3 induced by genotoxic stress pDDR foci are preferentially located at the
4 telomeres (Fumagalli et al. 2012, Hewitt et al. 2012). Interestingly, pDDR foci
5 have also been identified in non-telomeric regions, collectively called 'DNA
6 segments with chromatin alterations reinforcing senescence' (DNA-SCARS),
7 which also lack DNA repair proteins (Rodier et al. 2011). These DNA-SCARS
8 seem to be persistent double strand breaks that remain unrepaired (Galbiati
9 et al. 2017). Further, the pDDR has also been associated with other forms of
10 senescence including OIS, which typically exhibits an initial mitotic burst,
11 causing an S-phase-associated DDR (Bartkova et al. 2006, d'Adda di
12 Fagagna 2008, Di Micco et al. 2006, Mallette et al. 2007).

13

14 Although pDDR appears to underline many types of senescence, senescence
15 can be induced without a DDR. For example, ectopic expression of p16 or
16 p21 is able to drive a senescent phenotype without a DDR (Coppé et al.
17 2011). More recently, developmental senescence has also been found to be a
18 critical mediator of embryological development and is not associated with a
19 DDR (Muñoz-Espín et al. 2013, Storer et al. 2013).

20

21 It has also been suggested that the multiple nuclear and chromatin alterations
22 seen in senescence might be involved in underpinning the stable cell cycle
23 arrest (Salama et al. 2014). This was also highlighted in mouse genetic
24 models of OIS/TIS, where *Suv39h1* is essential for senescence: *Suv39h1* is a
25 histone H3 lysine 9 methyl-transferase, which marks heterochromatin (Braig

1 et al. 2005, Dörr et al. 2013). Although not described as a cancer hallmark,
2 epigenetics might be considered to be an ‘enabling characteristic’ for other
3 hallmarks. Another ‘autonomous’ effector, potentially associated with
4 senescence arrest is a metabolic switch: Senescence has a distinct metabolic
5 state compared to cancer, which is accompanied by ‘**deregulating cellular**
6 **energetics**’. We recently reviewed these features of senescence in detail:
7 epigenetics (Parry & Narita 2016); and metabolism (Pérez-Mancera et al.
8 2014). Interestingly, increasing evidence suggest interplay between them. For
9 example, senescence-specific downregulation of the nuclear lamina protein
10 Lamin B1 has been implicated in gene regulation and senescence-associated
11 heterochromatic foci (SAHF) formation during OIS (Sadaie et al. 2013). Lamin
12 B1 has recently been shown to be a substrate of autophagy (Dou et al. 2015),
13 a nutrient-sensing bulk-protein degradation process, demonstrated to be
14 activated during senescence (Young et al. 2009). In addition, histone-
15 modifying enzymes are often controlled by metabolic intermediates of
16 glycolysis and the tricarboxylic acid (TCA) cycle (Lu & Thompson 2012), both
17 of which appear to be hyper-activated during senescence (Dörr et al. 2013,
18 Kaplon et al. 2013). Although any causal link between senescence-associated
19 metabolic changes and histone modifications is unclear, such a link has been
20 highlighted in cancer by mutations of isocitrate dehydrogenases (IDH), which
21 normally metabolizes intermediates of the TCA cycle. Mutant IDH converts α -
22 ketoglutarate (α -KG) to 2-hydroxyglutarate (2-HG), which inhibits α -KG-
23 dependent enzyme activities. Such enzymes include the JmjC-domain family
24 of demethylases and TET proteins; thus, 2-HG inhibits the demethylation of
25 histones and DNA, respectively (Lu et al. 2012, Turcan et al. 2012).

1 Oncogenic mutations in another TCA cycle enzyme fumarate hydratase (FH)
2 have been shown to induce senescence (Zheng et al. 2015). The mechanism
3 for induction of this form of senescence appears to be oxidative stress, but it
4 would be interesting to know how such perturbation of the TCA cycle affects
5 the epigenetic state and chromatin structure of senescent cells.

6

7 **4. NON-AUTONOMOUS ACTIVITIES OF SENESCENCE**

8 Senescence was once viewed as a functional end point of stress response,
9 but senescent cells are able to express and secrete factors that can exert
10 profound effects upon surrounding players in the microenvironment, such as
11 parenchymal, stromal and immune cells, in addition to the extracellular matrix
12 (Fig. 1c). This secretome consists of a wide variety of cytokines, chemokines,
13 matrix-modifying enzymes and growth factors that have been linked with
14 diverse, sometimes contrasting, downstream functional outcomes in different
15 contexts. The SASP has been linked with outcomes in 6 different domains: (1)
16 tumor suppression through autocrine reinforcement of senescence; (2) tumor
17 suppression through paracrine transmission of senescence; (3) tumor
18 suppression through promotion of immune-mediated surveillance of
19 senescent cells; (4) oncogenesis through paracrine promotion of
20 tumorigenesis, through ‘**tumor-promoting inflammation**’; (5) paracrine
21 enhancement of ‘stemness’ and plasticity; (6) promotion of angiogenesis.

22

23 **4.1. Senescence and Immunity**

24 It has long been recognized that many cancers, such as viral hepatitis-related
25 hepatocellular carcinoma (HCC) or inflammatory bowel disease-related

1 colorectal carcinoma, can develop in the context of chronic tissue
2 inflammation (Coussens & Werb 2002). Further, inflammation and subsequent
3 immune cell infiltration portends an improved prognosis in several human
4 cancers (Pagès et al. 2010, Stanton et al. 2016). Inflammation not only
5 provides mitogenic stimulation, but also leads to modification of the
6 extracellular matrix and promotes angiogenesis; therefore, **'tumor-promoting
7 inflammation'** is proposed to be an enabling characteristic of other hallmarks
8 of carcinogenesis, and it is perhaps coupled with the hallmark, **'avoiding
9 immune destruction'** (Hanahan & Weinberg 2011). Increased evidence
10 suggests that senescence, either in tumor or stromal cells, is involved in both
11 of these processes.

12

13 Within the diverse factors of the SASP, inflammatory cytokines and
14 chemokines, including IL6, IL8, and IL1, have been used as a representative
15 subset. These factors are pleiotropic and, not surprisingly, have been reported
16 to contribute to diverse processes. One feature of activation of the
17 inflammatory SASP in vivo is immune cell recruitment and subsequent
18 immune-mediated clearance of senescent cells: senescent cells signal to
19 different components of the immune system to drive this process (Yevsa et al.
20 2012). The first evidence for this was shown in a 'TIS model' (in a broader
21 sense), where endogenous p53 is reactivated in fully established cancer (Xue
22 et al. 2007). In this study, embryonic mouse liver progenitor cells expressing
23 oncogenic H-RAS and tetracycline-responsive sh-p53 develop cancer when
24 they are seeded to the livers of mice lacking adaptive immunity; reactivation of
25 endogenous p53, by switching off the RNAi, results in tumor regression.

1 Interestingly, the primary response to the p53 restoration is not cell death but
2 senescence and a subsequent innate immune response that in turn targets
3 the senescent tumor cells. This is in contrast to the aforementioned *Eμ-myc-*
4 *Bcl2* lymphoma model, where the primary response to genotoxic
5 chemotherapy is p53-dependent senescence with no tumor regression
6 (Schmitt et al. 2002).

7

8 Pre-malignant OIS cells also have significant interactions with the immune
9 system (Kang et al. 2011). Hydrodynamic tail-vein delivery of NRAS^{G12V}-
10 containing transposons in the mouse results in mosaic integration and
11 induction of hepatocyte OIS, which is accompanied by the SASP-mediated
12 recruitment of immunocytes and subsequent clearance of senescent cells,
13 termed senescence surveillance (Kang et al. 2011). In the absence of
14 functional adaptive, and more specifically CD4⁺ T-lymphocyte, immunity
15 persistent RAS-senescent hepatocytes develop into HCC with reduced
16 expression of p19^{Arf}, a strong senescence effector in mice (Kang et al. 2011),
17 placing senescence surveillance as an additional tumor suppressive layer. A
18 more recent study showed that OIS hepatocyte-induced CCL2-CCR2
19 signaling promotes recruitment of immature myeloid cells (iMC) to the liver
20 and their differentiation to macrophages, likely to be the major effector cells
21 downstream of CD4⁺ T-helper cells, for elimination of OIS hepatocytes
22 (Eggert et al. 2016).

23

24 This model offers a unique opportunity to study the dynamic mechanisms
25 underpinning immune destruction and its avoidance, but as mentioned above,

1 earlier in vivo OIS studies do not describe immune elimination of senescent
2 cells (Narita & Lowe 2005). Thus, in both TIS and OIS, the efficiency of
3 senescence surveillance appears to be model dependent. The reason for the
4 variation of the long-term fate of senescent cells in vivo, either in TIS or OIS,
5 is unclear. In the liver OIS model, a CD4⁺ T-cell-dependent, mutant NRAS-
6 specific reaction critical for senescence surveillance develops in adult mice
7 after delivery of a genuinely novel tumor antigen. In other genetically modified
8 mouse models oncogenes (such as K-Ras and BRaf), mostly driven by
9 endogenous promoters, are expressed during embryonic development and
10 therefore may be ignored as self-antigens.

11

12 It is also possible that the SASP composition varies with different senescence
13 drivers. Indeed, in the context of senescence induced by the loss of *Pten* in
14 murine prostatic epithelial cells, the SASP is immunosuppressive when
15 compared to the immunostimulatory SASP of Ras-induced senescence in the
16 same tissue (Di Mitri et al. 2014, Toso et al. 2014). This *Pten*-loss SASP
17 drives the recruitment and function of myeloid-derived suppressor cells,
18 impairing CD8⁺ T-lymphocyte-mediated immune surveillance. Utilising
19 pharmacological inhibition of the JAK/STAT signalling pathway, it is possible
20 to reprogram the functional output of the SASP in order to repress this SASP-
21 dependent immunosuppressive microenvironment, promoting immune-
22 mediated clearance and improving cancer-related outcomes (Toso et al.
23 2014).

24

1 Furthermore, it was recently shown that functionally distinct secretomes are
2 dynamically regulated during the transition to OIS (Hoare et al. 2016).
3 NOTCH1, a highly conserved cell surface receptor, previously identified as
4 both oncogenic and tumor suppressive in different human cancers (Aster et
5 al. 2017), is transiently activated during the transition to senescence,
6 temporally associated with a phase of the SASP rich in TGF β ligands,
7 collagens and fibronectin. By full senescence, when the SASP includes pro-
8 inflammatory cytokines and fibrolytic matrix-modifying enzymes, NOTCH
9 activity had returned to baseline. Mechanistically NOTCH achieves this, in
10 part, through inhibition of C/EBP β , a key transcription factor controlling the
11 inflammatory SASP (see sidebar). Importantly, in the liver OIS surveillance
12 model (Kang et al. 2011), inhibiting Notch signaling in OIS hepatocytes
13 facilitates their immune clearance, possibly due to a shift towards a more
14 inflammatory SASP (Hoare et al. 2016), highlighting a therapeutic opportunity
15 to modulate SASP activity to control tumorigenesis.

16

17 These immunosuppressive aspects of the SASP, represented in the *Pten*
18 loss-induced prostate pre-neoplastic tumor (Toso et al. 2014) or NOTCH-type
19 SASP (Hoare et al. 2016) might explain, at least in part, the varying extent of
20 senescence surveillance depending on the model. This view might be
21 extended to the context of advanced cancer, where an immunosuppressive
22 SASP, derived from either senescent tumor or stromal cells could also be
23 involved in the cancer hallmark, '**avoiding immune destruction**' through
24 diverse mechanisms (Eggert et al. 2016, Ruhland et al. 2016). In recent
25 years, the recognition that anti-tumoral immunity is actively suppressed

1 through inhibitory immune check-points (such as PD-1 and CTLA4) has led to
2 an explosion in the interest in blocking these mechanisms to release the
3 endogenous anti-cancer function of the patients own immune system. It would
4 be interesting to know whether the SASP is also involved in this process.

5

6 In addition to the tumor suppressive consequence of OIS/TIS, it is important
7 to explore the opposite scenario, where senescent cells are the source of the
8 cancer hallmark, '**tumor promoting inflammation**'. The same SASP factors
9 have been shown to promote tumorigenesis or tumorigenic inflammation,
10 particularly for cells that have escaped senescence arrest in some contexts
11 (Jackson et al. 2012, Pribluda et al. 2013). In the liver OIS model mentioned
12 above (Kang et al. 2011), the same tumor suppressive environment that
13 eliminates OIS hepatocytes can also promote the growth of established HCC
14 cells. This is mediated through a combination of the SASP (CCL2) and HCC-
15 derived secretory factors: the former recruits iMC to the liver and the latter
16 inhibits subsequent differentiation of the immunosuppressive iMC into tumor
17 suppressive macrophages (Eggert et al. 2016), highlighting a complex
18 interaction between simultaneous secretomes derived from senescent and
19 tumor cells. This study also reinforces the varying impacts of the same SASP
20 on tumorigenesis depending on the cell receiving the signal.

21

22 **4.2. Senescence and Stroma**

23 In addition to senescence of parenchymal cells critically altering the
24 microenvironment, there is increasing evidence that senescence of stromal
25 cells within the tumor-microenvironment can modulate the fate of neighboring

1 cancer cells and cancer-related outcomes. In several culture and xenograft
2 models, senescent fibroblasts have been demonstrated to promote the
3 proliferation and invasiveness of neighboring epithelial tumor cell lines
4 through the SASP and stimulation of the epithelial-mesenchymal transition
5 (Bavik et al. 2006, Coppé et al. 2008, Krtolica et al. 2001, Parrinello et al.
6 2005), suggesting tumorigenic effects of the SASP on epithelial cells that are
7 already primed for transformation. In addition, senescence-reporter mice have
8 highlighted stromal senescence in some tumor models (Burd et al. 2013,
9 Yoshimoto et al. 2013).

10

11 **4.2.1. Stromal SASP and tumorigenesis.** The similar effects of stromal
12 senescence on established cancer have been shown in vivo. For example,
13 murine melanoma cell lines become more invasive and metastasized more
14 frequently when implanted into the skin of aged mice, with increased numbers
15 of senescent dermal fibroblasts (Kaur et al. 2016). Wnt signaling has been
16 implicated in melanoma ‘phenotype switching’ (i.e. switch between
17 proliferative and invasive states) (Webster et al. 2015), and this study showed
18 that sFRP2, a Wnt antagonist, secreted from these fibroblasts is critical for
19 melanoma invasion and metastasis in this model (Kaur et al. 2016). Stromal
20 senescence has also been shown to facilitate murine breast cancer
21 recurrence and metastasis after chemotherapy or surgical removal (Demaria
22 et al. 2017), suggesting that the stromal SASP contributes to the cancer
23 hallmark, ‘**activating invasion and metastasis**’. In these studies, the
24 interaction between stromal senescence and immunophenotypes was not
25 addressed. However, stromal SASP was reported to promote tumorigenesis

1 through immune modulation in a different model: stromal-specific induction of
2 senescence or skin-injection of senescent fibroblasts is sufficient to establish
3 a immunosuppressive microenvironment characterized by increasing myeloid-
4 derived suppressor cells that are capable of inhibiting CD8+ T-cell function
5 (Ruhland et al. 2016). This environment appears to promote growth of
6 injected murine tumor cell lines, supporting the potential role for senescence
7 in the '**avoiding immune destruction**' hallmark. Stromal senescence in
8 tumor-microenvironments was highlighted in a senescence-reporter mouse
9 model, and curiously, those senescent cells include bone-marrow derived
10 cells: the significance of a senescence-like state in these cells remains to be
11 elucidated (Burd et al. 2013).

12

13 While the stromal SASP is mostly tumorigenic, its impact on tumor 'initiation'
14 appears context-dependent. Senescence has been shown to play a key role
15 in tissue homeostasis and damage repair through the SASP (Demaria et al.
16 2014, Jun & Lau 2010, Krizhanovsky et al. 2008) and the same process could
17 also affect tumorigenesis. For example, in a mouse model of liver fibrosis
18 induced by the liver-damaging reagent, CCL4, quiescent hepatic stellate cells
19 (HSCs) differentiate into proliferative and fibrogenic myofibroblasts (activated
20 HSCs), which subsequently develop senescence with an inflammatory and
21 fibrolytic SASP. Thus, the SASP limits fibrosis and, and simultaneously,
22 recruits immune cells to eliminate the senescent HSCs (Krizhanovsky et al.
23 2008). In this context, chemically induced HCC development is limited through
24 tumor suppressive M1 macrophages. However, when HSCs escape
25 senescence, due to loss of p53, they secrete factors promoting polarization of

1 macrophages into a tumorigenic M2 state (Lujambio et al. 2013). HSCs can
2 also be induced to senescence in the context of genetic and dietary obesity,
3 where the gut microbiota is altered (Yoshimoto et al. 2013). These bacteria
4 induced increased concentrations of the toxic bile acid deoxy-cholic acid
5 (DCA), absorbed through the enterohepatic circulation and provoking the
6 SASP in HSCs. In contrast to the CCL4-liver damage model, the SASP in this
7 case promotes chemically-induced HCC.

8

9 The opposing effects of the HSC-SASP on HCC development in these two
10 models might be, in part, due to the different metabolic state. The extent of
11 liver damage and fibrosis, the latter appearing absent in the obesity model,
12 might also need to be considered. These factors might affect the nature of the
13 immune microenvironment, particularly at the initial stage of tumorigenesis,
14 potentially an important determinant for the difference in long-term
15 tumorigenic effects of SASP. Interestingly, the shift from fibrogenic to fibrolytic
16 secretome in HSCs during senescence development in the CCL4 model is
17 reminiscent of the NOTCH-regulated SASP switch described above (Hoare et
18 al. 2016) and NOTCH-mediated stromal senescence was noted in a skin
19 cancer model (Procopio et al. 2015). Detailed analysis of the dynamic and
20 context-dependent stromal SASP-immune axis might help to reconcile this
21 question.

22

23 **4.2.3. Senescence and cellular re-programing.** One potential mechanism
24 for the non-autonomous tumor-promoting activity of senescence is the
25 recently recognized role that senescence and the SASP plays in controlling

1 differentiation and the ability to re-program into different cellular fates (Chiche
2 et al. 2017, Mosteiro et al. 2016, Ocampo et al. 2016, Ritschka et al. 2017).

3

4 Somatic cells can be re-programed into induced pluripotent stem cells in
5 response to expression of the four Yamanaka factors: Oct3/4; Sox2; Klf4; c-
6 Myc (OSKM). It was previously shown that senescence is a barrier to re-
7 programing in culture (reviewed in (Salama et al. 2014)). Paradoxically, a
8 recent series of studies indicate that OSKM-mediated reprograming does
9 occur or even is facilitated in the context of aging or senescence in vivo
10 (Chiche et al. 2017, Mosteiro et al. 2016, Ocampo et al. 2016, Ritschka et al.
11 2017). Mosteiro et al. show that the OSKM induction in vivo is associated, not
12 only with reprograming, but also extensive tissue damage and the
13 development of senescent cells within the same microenvironment, where
14 reprograming tends to occur in close proximity to more abundant senescent
15 cells (Chiche et al. 2017, Mosteiro et al. 2016). Loss of the $p16^{INK4A}/p19^{ARF}$
16 locus, which abrogates the senescence barrier, thus enhancing reprograming
17 in vitro, suppresses in vivo reprograming (Mosteiro et al. 2016). These
18 observations suggest that reprograming of ‘some cells’ is promoted indirectly
19 by neighboring senescent cells in vivo. Indeed, selective killing of senescent
20 cells also suppresses in vivo reprograming (Chiche et al. 2017, Mosteiro et al.
21 2016). Consistently, the researchers identified that the SASP (IL6 in
22 particular) facilitates in vivo reprograming. Thus, senescence is both an
23 autonomous barrier and non-autonomous promoter of reprograming (Chiche
24 et al. 2017, Mosteiro et al. 2016).

25

1 Then which cells are preferentially reprogrammed? Using the same inducible
2 OSKM mice, Chiche et al. show that, in skeletal muscle, reprogramming occurs
3 during muscle regeneration after damage, which triggers senescence.
4 Reprogramming mostly occurs in satellite cells, suggesting that progenitor/stem
5 cells are the preferential origin for reprogramming at least in skeletal muscle
6 (Chiche et al. 2017).

7

8 While these studies used ‘reprogrammable mice’, a similar observation was
9 made in OIS models. Ritschka et al. showed that transient exposure to
10 senescent-conditioned media induces a stem cell-like gene signature within
11 differentiated keratinocytes (Ritschka et al. 2017). Thus, senescence induced
12 after tissue damage is crucial for co-ordinating the response of immune cells
13 to limit damage, but also for promoting regeneration through induction of
14 stemness and tissue proliferation, a feature that might be utilized by cancer in
15 some contexts.

16

17 **4.2.2. Senescence and the vasculature. ‘Angiogenesis’** is a critical
18 hallmark of most cancers, where increased vascularization provides the
19 increased oxygen and nutrient delivery to permit tumor development and
20 progression. Senescence has been demonstrated to modulate angiogenesis
21 in both benign degenerative and malignant diseases through the SASP.
22 Elimination of senescent cells from the murine skin wound healing model
23 leads to a reduction in angiogenesis within the healing wound (Demaria et al.
24 2014). Senescent fibroblasts produce VEGF, a potent trophic factor for
25 vascular growth and angiogenesis (Coppé et al. 2006); when co-injected with

1 tumor cells, senescent fibroblasts promote increased tumor vascularization
2 compared to non-senescent fibroblasts (Coppé et al. 2006). Senescence-
3 induced angiogenesis has been demonstrated in other models. Retinal
4 ischaemia, frequently induced by diabetes mellitus and a major cause of sight
5 loss, is associated with the development of both retinal cell senescence and
6 secretion of VEGF, in a mouse model (Oubaha et al. 2016). Therapeutically,
7 antibody-mediated depletion of VEGF reduced progression of the retinopathy
8 in this model. In the field of cancer, multiple myeloma is able to induce stromal
9 cell senescence and subsequent secretion of FGF2 which underpins
10 increased growth and angiogenesis of xenografted myeloma tumors
11 (Kanehira et al. 2016). Senescent dermal fibroblasts, through secretion of
12 sFRP2, are also able to provoke increased vascularization of implanted
13 melanoma tumors (Kaur et al. 2016).

14

15 **5. SENESENCE AS THERAPEUTIC TARGET IN CANCER**

16 As discussed earlier, TIS represents the therapeutic induction of senescence
17 in fully transformed cells. TIS typically implies genotoxic chemotherapy-
18 induced senescence, but this has been extended. For example, p16 acts to
19 inhibit CDK4/6, which are activated or amplified in several human cancer
20 types and therefore the development of specific inhibitors, such as palbociclib,
21 hold promise as negative regulators of cellular proliferation and therapeutic
22 inducers of senescence (O'Leary et al. 2016). In the context of breast cancer
23 the addition of palbociclib to conventional treatment led to a doubling of
24 progression-free survival (Finn et al. 2015, Turner et al. 2015). In melanoma,
25 palbociclib is able to induce cellular senescence, even in the context of

1 tumors that are resistant to the BRAF^{V600E} inhibitor vemurafenib (Yoshida et
2 al. 2016).

3

4 However, TIS often involves complex non-autonomous activities, of which net
5 impact on the cancer microenvironment is difficult to predict. One approach
6 could be to exploit the autonomous arrest of senescence with minimal SASP
7 induction. In addition to TIS, effectors of senescence surveillance could be a
8 potential target to enhance this process, as exemplified by NOTCH inhibition
9 in OIS hepatocytes (discussed above) (Hoare et al. 2016). But, here we focus
10 on an alternative avenue that has gained increasing attention: targeted killing
11 of senescent cells (or ‘senolytics’) of either tumoral or stromal origin. The
12 pioneering work in this area was made in aging contexts: elimination of
13 senescent cells in genetically-modified mice, which harbor *INK-ATTAC*, the
14 ‘killing cassette’ for inducible apoptosis in p16-expressing senescent cells,
15 extends healthy life span in both premature and naturally aging mice (Baker et
16 al. 2011, 2016).

17

18 Following this initial genetic approach, several small molecules have been
19 identified that ‘selectively’ kill senescent cells (Baar et al. 2017, Chang et al.
20 2016, Yosef et al. 2016, Zhu et al. 2015). Senescent cells are known to be
21 relatively resistant to apoptosis and transcriptional analyses have revealed
22 upregulation of several anti-apoptotic factors in some (Yosef et al. 2016, Zhu
23 et al. 2015), but not all contexts (Baar et al. 2017). Targeting these anti-
24 apoptotic survival pathways with dasatinib and quercetin (Zhu et al. 2015) or
25 ABT-263/ABT-737 (pan-Bcl inhibitors) (Chang et al. 2016, Yosef et al. 2016)

1 leads to reduced viability of senescent, but not proliferating cells. Similar to
2 the *INK-ATTAC* model, treatment of aged or irradiated mice with these
3 compounds results in fewer senescent cells, as well as some improvements in
4 organ functions.

5

6 More recently, a novel senolytic agent has been developed: a modified
7 FOXO4 peptide, FOXO4-D-Retro-Inverso (DRI), which interferes with
8 FOXO4-p53 binding (Baar et al. 2017). Treatment with FOXO4-DRI releases
9 active p53, which is excluded from the nucleus, triggering apoptosis in
10 senescent cells, presumably through recruitment of active p53 to
11 mitochondria. Additionally, treatment with FOXO4-DRI in vivo reduces the
12 burden of senescent cells and restores physical fitness, hair density and renal
13 function in both premature and natural aged mice.

14

15 Such ‘rejuvenation’ effects of senolytics in mice are highly promising. In the
16 natural aging context, clearance of senescent cells in the *INK-ATTAC* mouse
17 does not reduce the overall lifetime incidence of cancer, but it significantly
18 increases both cancer- and non-cancer-related survival (Baker et al. 2016).
19 However, the efficacy of selectively killing senescent tumor cells (e.g. tumor
20 TIS plus senolytics) remains to be tested. Nevertheless, mice without cancer,
21 treated with doxorubicin, a standard anti-cancer agent, developed systemic
22 senescence and impaired physical function, that could be rescued by
23 elimination of the senescent cells either by FOXO4-DRI or in a second genetic
24 mouse model, *p16-3MR*, containing a thymidine kinase, which kills p16-
25 expressing cells in the presence of ganciclovir (GCV). Thus, senescence

1 elimination can neutralize the side-effects of chemotherapy (Demaria et al.
2 2017). Furthermore, when the *p16-3MR* mice, implanted with a murine breast
3 cancer cell line (with no *p16-3MR*) are treated with the chemotherapy with or
4 without GCV, mice with GCV show better survival with a lower frequency of
5 metastasis (Demaria et al. 2017). Thus, clearance of senescent cells either for
6 preventing the development of cancer or reducing the toxicity of
7 chemotherapy regimes is also a potential therapeutic target.

8 **SUMMARY POINTS:**

- 9 1. The hallmarks of cancer describe the mechanisms underlying the
10 transformation of cells from normal to cancer. Senescence may underpin a
11 number of these hallmarks.
- 12 2. Senescence is an autonomous tumor suppressor, leading to long-term cell
13 cycle arrest. Senescence can develop after oncogene activation, loss of tumor
14 suppressors or anti-cancer therapies.
- 15 3. Through the senescence-associated secretory phenotype (SASP),
16 senescent cells have myriad effects upon the microenvironment that can be
17 pro- or anti-tumorigenic.
- 18 4. Through the SASP, senescent cells trigger their own immune-mediated
19 destruction; if this process is interrupted, persistent senescent cells are
20 tumorigenic.
- 21 5. Senescence is a potential therapeutic target, through modulation of the
22 composition of the SASP or targeted killing of senescent cells to prevent
23 cancer or the side effects of anti-cancer therapies.

24

25 **FUTURE ISSUES:**

26 Some of the most pressing research needs in the field of senescence and

1 cancer are:

2 1. The development of ‘pure’ autonomous senescence inducers;

3 2. Understanding the context-dependent nature of the SASP in different

4 stages of cancer development; what are the mechanisms of antagonist

5 secretomes in the same microenvironment?

6 3. The development of diverse methods for ‘mechanism-guided’ senescence

7 elimination;

8 4. Understanding the effects of senolytics on (pre)neoplastic senescence in

9 vivo.

10

11 **DISCLOSURE STATEMENT**

12 The author is not aware of any affiliations, memberships, funding, or financial

13 holdings that might be perceived as affecting the objectivity of this review.

14

15 **ACKNOWLEDGMENTS**

16 We thank members of the Narita lab for comments on this review. MH is

17 supported by a CRUK Clinician Scientist Fellowship (C52489/A19924). MN is

18 supported by a Cancer Research UK Cambridge Centre Core Grant

19 (C14303/A17197).

1 **REFERENCES**

- 2 Acosta JC, Banito A, Wuestefeld T, Georgilis A, Janich P, et al. 2013. A
3 complex secretory program orchestrated by the inflammasome controls
4 paracrine senescence. *Nature Cell Biology*. 15(8):978–90
- 5 Acosta JC, O’Loghlen A, Banito A, Guijarro MV, Augert A, et al. 2008.
6 Chemokine signaling via the CXCR2 receptor reinforces senescence.
7 *Cell*. 133(6):1006–18
- 8 Aird KM, Iwasaki O, Kossenkov AV, Tanizawa H, Fatkhutdinov N, et al. 2016.
9 HMGB2 orchestrates the chromatin landscape of senescence-associated
10 secretory phenotype gene loci. *The Journal of Cell Biology*. 215(3):325–34
- 11 Alcorta DA, Xiong Y, Phelps D, Hannon G, Beach D, Barrett JC. 1996.
12 Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in
13 replicative senescence of normal human fibroblasts. *Proc. Natl. Acad. Sci.*
14 *U.S.A.* 93(24):13742–47
- 15 Aster JC, Pear WS, Blacklow SC. 2017. The Varied Roles of Notch in Cancer.
16 *Annu Rev Pathol*. 12(1):245–75
- 17 Baar MP, Brandt RMC, Putavet DA, Klein JDD, Derks KWJ, et al. 2017.
18 Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in
19 Response to Chemotoxicity and Aging. *Cell*. 169(1):132–147.e16
- 20 Bae NS, Baumann P. 2007. A RAP1/TRF2 complex inhibits nonhomologous
21 end-joining at human telomeric DNA ends. *Molecular Cell*. 26(3):323–34
- 22 Baker DJ, Childs BG, Durik M, Wijers ME, Sieben CJ, et al. 2016. Naturally
23 occurring p16(Ink4a)-positive cells shorten healthy lifespan. *Nature*.
24 530(7589):184–89
- 25 Baker DJ, Wijshake T, Tchkonja T, LeBrasseur NK, Childs BG, et al. 2011.
26 Clearance of p16Ink4a-positive senescent cells delays ageing-associated
27 disorders. *Nature*. 479(7372):232–36
- 28 Bartkova J, Rezaei N, Liontos M, Karakaidos P, Kletsas D, et al. 2006.
29 Oncogene-induced senescence is part of the tumorigenesis barrier
30 imposed by DNA damage checkpoints. *Nature*. 444(7119):633–37
- 31 Bavik C, Coleman I, Dean JP, Knudsen B, Plymate S, Nelson PS. 2006. The
32 gene expression program of prostate fibroblast senescence modulates
33 neoplastic epithelial cell proliferation through paracrine mechanisms.
34 *Cancer Research*. 66(2):794–802
- 35 Brady CA, Jiang D, Mello SS, Johnson TM, Jarvis LA, et al. 2011. Distinct p53
36 Transcriptional Programs Dictate Acute DNA-Damage Responses and
37 Tumor Suppression. *Cell*. 145(4):571–83
- 38 Braig M, Lee S, Loddenkemper C, Rudolph C, Peters AHFM, et al. 2005.
39 Oncogene-induced senescence as an initial barrier in lymphoma
40 development. *Nature*. 436(7051):660–65
- 41 Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T, Hannon GJ.
42 1995. Radiation-induced cell cycle arrest compromised by p21 deficiency.
43 *Nature*. 377(6549):552–57
- 44 Burd CE, Sorrentino JA, Clark KS, Darr DB, Krishnamurthy J, et al. 2013.
45 Monitoring tumorigenesis and senescence in vivo with a p16(INK4a)-
46 luciferase model. *Cell*. 152(1-2):340–51
- 47 Chang J, Wang Y, Shao L, Laberge R-M, Demaria M, et al. 2016. Clearance
48 of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells
49 in mice. *Nature Medicine*. 22(1):78–83

- 1 Chen Z, Trotman LC, Shaffer D, Lin H-K, Dotan ZA, et al. 2005. Crucial role of
2 p53-dependent cellular senescence in suppression of Pten-deficient
3 tumorigenesis. *Nature*. 436(7051):725–30
- 4 Chiche A, Le Roux I, Joest von M, Sakai H, Aguín SB, et al. 2017. Injury-
5 Induced Senescence Enables In Vivo Reprogramming in Skeletal Muscle.
6 *Cell Stem Cell*. 20(3):407–414.e4
- 7 Christophorou MA, Ringshausen I, Finch AJ, Swigart LB, Evan GI. 2006. The
8 pathological response to DNA damage does not contribute to p53-
9 mediated tumour suppression. *Nature*. 443(7108):214–17
- 10 Collado M, Blasco MA, Serrano M. 2007. Cellular senescence in cancer and
11 aging. *Cell*. 130(2):223–33
- 12 Collado M, Gil J, Efeyan A, Guerra C, Schuhmacher AJ, et al. 2005. Tumour
13 biology: senescence in premalignant tumours. *Nature*. 436(7051):642
- 14 Collado M, Serrano M. 2010. Senescence in tumours: evidence from mice
15 and humans. *Nat Rev Cancer*. 10(1):51–57
- 16 Coppé J-P, Kauser K, Campisi J, Beauséjour CM. 2006. Secretion of vascular
17 endothelial growth factor by primary human fibroblasts at senescence. *J*
18 *Biol. Chem*. 281(40):29568–74
- 19 Coppé J-P, Patil CK, Rodier F, Sun Y, Muñoz DP, et al. 2008. Senescence-
20 associated secretory phenotypes reveal cell-nonautonomous functions of
21 oncogenic RAS and the p53 tumor suppressor. *Plos Biol*. 6(12):2853–68
- 22 Coppé J-P, Rodier F, Patil CK, Freund A, Desprez P-Y, Campisi J. 2011.
23 Tumor suppressor and aging biomarker p16(INK4a) induces cellular
24 senescence without the associated inflammatory secretory phenotype.
25 *Journal of Biological Chemistry*. 286(42):36396–403
- 26 Cosme-Blanco W, Shen M-F, Lazar AJF, Pathak S, Lozano G, et al. 2007.
27 Telomere dysfunction suppresses spontaneous tumorigenesis in vivo by
28 initiating p53-dependent cellular senescence. *EMBO Rep*. 8(5):497–503
- 29 Courtois-Cox S, Genter Williams SM, Reczek EE, Johnson BW,
30 McGillicuddy LT, et al. 2006. A negative feedback signaling network
31 underlies oncogene-induced senescence. *Cancer Cell*. 10(6):459–72
- 32 Coussens LM, Werb Z. 2002. Inflammation and cancer. *Nature*.
33 420(6917):860–67
- 34 Czabotar PE, Lessene G, Strasser A, Adams JM. 2014. Control of apoptosis
35 by the BCL-2 protein family: implications for physiology and therapy. *Nat*
36 *Rev Mol Cell Biol*. 15(1):49–63
- 37 d'Adda di Fagagna F. 2008. Living on a break: cellular senescence as a DNA-
38 damage response. *Nat Rev Cancer*. 8(7):512–22
- 39 d'Adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, et al.
40 2003. A DNA damage checkpoint response in telomere-initiated
41 senescence. *Nature*. 426(6963):194–98
- 42 Demaria M, O'Leary MN, Chang J, Shao L, Liu S, et al. 2017. Cellular
43 Senescence Promotes Adverse Effects of Chemotherapy and Cancer
44 Relapse. *Cancer Discov*. 7(2):165–76
- 45 Demaria M, Ohtani N, Youssef SA, Rodier F, Toussaint W, et al. 2014. An
46 essential role for senescent cells in optimal wound healing through
47 secretion of PDGF-AA. *Developmental Cell*. 31(6):722–33
- 48 Di Micco R, Fumagalli M, Cicalese A, Piccinin S, Gasparini P, et al. 2006.
49 Oncogene-induced senescence is a DNA damage response triggered by
50 DNA hyper-replication. *Nature*. 444(7119):638–42

- 1 Di Mitri D, Toso A, Chen JJ, Sarti M, Pinton S, et al. 2014. Tumour-infiltrating
2 Gr-1+ myeloid cells antagonize senescence in cancer. *Nature*.
3 515(7525):134–37
- 4 Dou Z, Xu C, Donahue G, Shimi T, Pan J-A, et al. 2015. Autophagy mediates
5 degradation of nuclear lamina. *Nature*. 527(7576):105–9
- 6 Dörr JR, Yu Y, Milanovic M, Beuster G, Zasada C, et al. 2013. Synthetic lethal
7 metabolic targeting of cellular senescence in cancer therapy. *Nature*.
8 501(7467):421–25
- 9 Eggert T, Wolter K, Ji J, Ma C, Yevsa T, et al. 2016. Distinct Functions of
10 Senescence-Associated Immune Responses in Liver Tumor Surveillance
11 and Tumor Progression. *Cancer Cell*. 30(4):533–47
- 12 Feldser DM, Greider CW. 2007. Short telomeres limit tumor progression in
13 vivo by inducing senescence. *Cancer Cell*. 11(5):461–69
- 14 Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, et al. 2015. The cyclin-
15 dependent kinase 4/6 inhibitor palbociclib in combination with letrozole
16 versus letrozole alone as first-line treatment of oestrogen receptor-
17 positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18):
18 a randomised phase 2 study. *Lancet Oncol*. 16(1):25–35
- 19 Freund A, Patil CK, Campisi J. 2011. p38MAPK is a novel DNA damage
20 response-independent regulator of the senescence-associated secretory
21 phenotype. *The EMBO Journal*. 30(8):1536–48
- 22 Fumagalli M, Rossiello F, Clerici M, Barozzi S, Cittaro D, et al. 2012.
23 Telomeric DNA damage is irreparable and causes persistent DNA-
24 damage-response activation. *Nature Cell Biology*. 14(4):355–65
- 25 Fumagalli M, Rossiello F, Mondello C, d'Adda di Fagagna F. 2014. Stable
26 cellular senescence is associated with persistent DDR activation. *PLoS*
27 *ONE*. 9(10):e110969
- 28 Galbiati A, Beauséjour C, d'Adda di Fagagna F. 2017. A novel single-cell
29 method provides direct evidence of persistent DNA damage in senescent
30 cells and aged mammalian tissues. *Aging Cell*. 16(2):422–27
- 31 Gil J, Peters G. 2006. Regulation of the INK4b-ARF-INK4a tumour suppressor
32 locus: all for one or one for all. *Nat Rev Mol Cell Biol*. 7(9):667–77
- 33 Gray-Schopfer VC, Cheong SC, Chong H, Chow J, Moss T, et al. 2006.
34 Cellular senescence in naevi and immortalisation in melanoma: a role for
35 p16? *Br J Cancer*. 95(4):496–505
- 36 Hanahan D, Weinberg RA. 2000. The hallmarks of cancer. *Cell*. 100(1):57–70
- 37 Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation.
38 *Cell*. 144(5):646–74
- 39 Harley CB, Futcher AB, Greider CW. 1990. Telomeres shorten during ageing
40 of human fibroblasts. *Nature*. 345(6274):458–60
- 41 HAYFLICK L. 1965. THE LIMITED IN VITRO LIFETIME OF HUMAN DIPLOID
42 CELL STRAINS. *Experimental Cell Research*. 37:614–36
- 43 Herbig U, Jobling WA, Chen BPC, Chen DJ, Sedivy JM. 2004. Telomere
44 shortening triggers senescence of human cells through a pathway
45 involving ATM, p53, and p21(CIP1), but not p16(INK4a). *Molecular Cell*.
46 14(4):501–13
- 47 Herranz N, Gallage S, Mellone M, Wuestefeld T, Klotz S, et al. 2015. mTOR
48 regulates MAPKAPK2 translation to control the senescence-associated
49 secretory phenotype. *Nature Cell Biology*. 17(9):1205–17
- 50 Hewitt G, Jurk D, Marques FDM, Correia-Melo C, Hardy T, et al. 2012.

- 1 Telomeres are favoured targets of a persistent DNA damage response in
2 ageing and stress-induced senescence. *Nat Commun.* 3:708
- 3 Hoare M, Ito Y, Kang T-W, Weekes MP, Matheson NJ, et al. 2016. NOTCH1
4 mediates a switch between two distinct secretomes during senescence.
5 *Nature Cell Biology.* 18(9):979–92
- 6 Jackson JG, Pant V, Li Q, Chang LL, Quintás-Cardama A, et al. 2012. p53-
7 mediated senescence impairs the apoptotic response to chemotherapy
8 and clinical outcome in breast cancer. *Cancer Cell.* 21(6):793–806
- 9 Johmura Y, Nakanishi M. 2016. Multiple facets of p53 in senescence
10 induction and maintenance. *Cancer Science.* 107(11):1550–55
- 11 Jun J-I, Lau LF. 2010. The matricellular protein CCN1 induces fibroblast
12 senescence and restricts fibrosis in cutaneous wound healing. *Nature Cell*
13 *Biology.* 12(7):676–85
- 14 Kanehira M, Fujiwara T, Nakajima S, Okitsu Y, Onishi Y, et al. 2016. An
15 Lysophosphatidic Acid Receptors 1 and 3 Axis Governs Cellular
16 Senescence of Mesenchymal Stromal Cells and Promotes Growth and
17 Vascularization of Multiple Myeloma. *Stem Cells.* 35(3):739–53
- 18 Kang C, Xu Q, Martin TD, Li MZ, Demaria M, et al. 2015. The DNA damage
19 response induces inflammation and senescence by inhibiting autophagy
20 of GATA4. *Science.* 349(6255):aaa5612
- 21 Kang T-W, Yevsa T, Woller N, Hoenicke L, Wuestefeld T, et al. 2011.
22 Senescence surveillance of pre-malignant hepatocytes limits liver cancer
23 development. *Nature.* 479(7374):547–51
- 24 Kaplon J, Zheng L, Meissl K, Chaneton B, Selivanov VA, et al. 2013. A key
25 role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-
26 induced senescence. *Nature.* 498(7452):109–12
- 27 Karlseder J, Smogorzewska A, de Lange T. 2002. Senescence induced by
28 altered telomere state, not telomere loss. *Science.* 295(5564):2446–49
- 29 Kaur A, Webster MR, Marchbank K, Behera R, Ndoye A, et al. 2016. sFRP2
30 in the aged microenvironment drives melanoma metastasis and therapy
31 resistance. *Nature.* 532(7598):250–54
- 32 Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, et al. 1994.
33 Specific association of human telomerase activity with immortal cells and
34 cancer. *Science.* 266(5193):2011–15
- 35 Kirschner K, Samarajiwa SA, Cairns JM, Menon S, Pérez-Mancera PA, et al.
36 2015. Phenotype Specific Analyses Reveal Distinct Regulatory
37 Mechanism for Chronically Activated p53. *PLoS Genet.* 11(3):e1005053
- 38 Kortlever RM, Higgins PJ, Bernards R. 2006. Plasminogen activator inhibitor-
39 1 is a critical downstream target of p53 in the induction of replicative
40 senescence. *Nature Cell Biology.* 8(8):877–84
- 41 Krizhanovsky V, Yon M, Dickins RA, Hearn S, Simon J, et al. 2008.
42 Senescence of activated stellate cells limits liver fibrosis. *Cell.*
43 134(4):657–67
- 44 Krtolica A, Parrinello S, Lockett S, Desprez PY, Campisi J. 2001. Senescent
45 fibroblasts promote epithelial cell growth and tumorigenesis: a link
46 between cancer and aging. *Proc Natl Acad Sci USA.* 98(21):12072–77
- 47 Kruse J-P, Gu W. 2009. Modes of p53 regulation. *Cell.* 137(4):609–22
- 48 Kuilman T, Michaloglou C, Vredeveld LCW, Douma S, van Doorn R, et al.
49 2008. Oncogene-induced senescence relayed by an interleukin-
50 dependent inflammatory network. *Cell.* 133(6):1019–31

- 1 Laberge R-M, Sun Y, Orjalo AV, Patil CK, Freund A, et al. 2015. mTOR
2 regulates the pro-tumorigenic senescence-associated secretory
3 phenotype by promoting IL1A translation. *Nature Cell Biology*.
4 17(8):1049–61
- 5 LaPak KM, Burd CE. 2014. The molecular balancing act of p16(INK4a) in
6 cancer and aging. *Mol. Cancer Res.* 12(2):167–83
- 7 Lazzerini Denchi E, Attwooll C, Pasini D, Helin K. 2005. Deregulated E2F
8 activity induces hyperplasia and senescence-like features in the mouse
9 pituitary gland. *Mol. Cell. Biol.* 25(7):2660–72
- 10 Levine AJ, Oren M. 2009. The first 30 years of p53: growing ever more
11 complex. *Nat Rev Cancer.* 9(10):749–58
- 12 Lin AW, Barradas M, Stone JC, van Aelst L, Serrano M, Lowe SW. 1998.
13 Premature senescence involving p53 and p16 is activated in response to
14 constitutive MEK/MAPK mitogenic signaling. *Genes & Development*.
15 12(19):3008–19
- 16 Lu C, Thompson CB. 2012. Metabolic regulation of epigenetics. *Cell Metab.*
17 16(1):9–17
- 18 Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, et al. 2012. IDH mutation
19 impairs histone demethylation and results in a block to cell differentiation.
20 *Nature.* 483(7390):474–78
- 21 Lujambio A, Akkari L, Simon J, Grace D, Tschaharganeh DF, et al. 2013.
22 Non-Cell-Autonomous Tumor Suppression by p53. *Cell.* 153(2):449–60
- 23 Mallette FA, Gaumont-Leclerc M-F, Ferbeyre G. 2007. The DNA damage
24 signaling pathway is a critical mediator of oncogene-induced senescence.
25 *Genes & Development.* 21(1):43–48
- 26 Michaloglou C, Vredeveld LCW, Soengas MS, Denoyelle C, Kuilman T, et al.
27 2005. BRAFE600-associated senescence-like cell cycle arrest of human
28 naevi. *Nature.* 436(7051):720–24
- 29 Mosteiro L, Pantoja C, Alcazar N, Marión RM, Chondronasiou D, et al. 2016.
30 Tissue damage and senescence provide critical signals for cellular
31 reprogramming in vivo. *Science.* 354(6315):
- 32 Muñoz-Espín D, Cañamero M, Maraver A, Gómez-López G, Contreras J, et
33 al. 2013. Programmed cell senescence during mammalian embryonic
34 development. *Cell.* 155(5):1104–18
- 35 Narita M, Lowe SW. 2005. Senescence comes of age. *Nature Medicine*,
36 Sep., pp. 920–22
- 37 Narita M, Young ARJ, Arakawa S, Samarajiwa SA, Nakashima T, et al. 2011.
38 Spatial coupling of mTOR and autophagy augments secretory
39 phenotypes. *Science.* 332(6032):966–70
- 40 O'Leary B, Finn RS, Turner NC. 2016. Treating cancer with selective CDK4/6
41 inhibitors. *Nat Rev Clin Oncol.* 13(7):417–30
- 42 Ocampo A, Reddy P, Martinez-Redondo P, Platero-Luengo A, Hatanaka F, et
43 al. 2016. In Vivo Amelioration of Age-Associated Hallmarks by Partial
44 Reprogramming. *Cell.* 167(7):1719–1733.e12
- 45 Orjalo AV, Bhaumik D, Gengler BK, Scott GK, Campisi J. 2009. Cell surface-
46 bound IL-1alpha is an upstream regulator of the senescence-associated
47 IL-6/IL-8 cytokine network. *Proc. Natl. Acad. Sci. U.S.A.* 106(40):17031–
48 36
- 49 Oubaha M, Miloudi K, Dejda A, Guber V, Mawambo G, et al. 2016.
50 Senescence-associated secretory phenotype contributes to pathological

- 1 angiogenesis in retinopathy. *Sci Transl Med.* 8(362):362ra144–44
2 Pagès F, Galon J, Dieu-Nosjean M-C, Tartour E, Sautès-Fridman C, Fridman
3 W-H. 2010. Immune infiltration in human tumors: a prognostic factor that
4 should not be ignored. *Nature Publishing Group.* 29(8):1093–1102
5 Parrinello S, Coppé J-P, Krtolica A, Campisi J. 2005. Stromal-epithelial
6 interactions in aging and cancer: senescent fibroblasts alter epithelial cell
7 differentiation. *Journal of Cell Science.* 118(Pt 3):485–96
8 Parry AJ, Narita M. 2016. Old cells, new tricks: chromatin structure in
9 senescence. *Mamm. Genome.* 27(7-8):320–31
10 Pérez-Mancera PA, Young ARJ, Narita M. 2014. Inside and out: the activities
11 of senescence in cancer. *Nat Rev Cancer.* 14(8):547–58
12 Poele te RH, Okorokov AL, Jardine L, Cummings J, Joel SP. 2002. DNA
13 damage is able to induce senescence in tumor cells in vitro and in vivo.
14 *Cancer Research.* 62(6):1876–83
15 Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, et al. 2003. High
16 frequency of BRAF mutations in nevi. *Nature Genetics.* 33(1):19–20
17 Pribluda A, Elyada E, Wiener Z, Hamza H, Goldstein RE, et al. 2013. A
18 Senescence-Inflammatory Switch from Cancer-Inhibitory to Cancer-
19 Promoting Mechanism. *Cancer Cell*
20 Procopio M-G, Laszlo C, Labban AI D, Kim DE, Bordignon P, et al. 2015.
21 Combined CSL and p53 downregulation promotes cancer-associated
22 fibroblast activation. *Nature Cell Biology.* 17(9):1193–1204
23 Ritschka B, Storer M, Mas A, Heinzmann F, Ortells MC, et al. 2017. The
24 senescence-associated secretory phenotype induces cellular plasticity
25 and tissue regeneration. *Genes & Development*
26 Rodier F, Coppé J-P, Patil CK, Hoeijmakers WAM, Muñoz DP, et al. 2009.
27 Persistent DNA damage signalling triggers senescence-associated
28 inflammatory cytokine secretion. *Nature Cell Biology.* 11(8):973–79
29 Rodier F, Muñoz DP, Teachenor R, Chu V, Le O, et al. 2011. DNA-SCARS:
30 distinct nuclear structures that sustain damage-induced senescence
31 growth arrest and inflammatory cytokine secretion. *Journal of Cell*
32 *Science.* 124(Pt 1):68–81
33 Rudolph KL, Chang S, Lee HW, Blasco M, Gottlieb GJ, et al. 1999. Longevity,
34 stress response, and cancer in aging telomerase-deficient mice. *Cell.*
35 96(5):701–12
36 Rufini A, Tucci P, Celardo I, Melino G. 2013. Senescence and aging: the
37 critical roles of p53. *Nature Publishing Group.* 32(43):5129–43
38 Ruhland MK, Loza AJ, Capietto A-H, Luo X, Knolhoff BL, et al. 2016. Stromal
39 senescence establishes an immunosuppressive microenvironment that
40 drives tumorigenesis. *Nat Commun.* 7:11762
41 Sadaie M, Salama R, Carroll T, Tomimatsu K, Chandra T, et al. 2013.
42 Redistribution of the Lamin B1 genomic binding profile affects
43 rearrangement of heterochromatic domains and SAHF formation during
44 senescence. *Genes & Development.* 27(16):1800–1808
45 Salama R, Sadaie M, Hoare M, Narita M. 2014. Cellular senescence and its
46 effector programs. *Genes & Development.* 28(2):99–114
47 Schmitt CA, Fridman JS, Yang M, Lee S, Baranov E, et al. 2002. A
48 senescence program controlled by p53 and p16INK4a contributes to the
49 outcome of cancer therapy. *Cell.* 109(3):335–46
50 Scurr LL, Pupo GM, Becker TM, Lai K, Schrama D, et al. 2010. IGFBP7 is not

- 1 required for B-RAF-induced melanocyte senescence. *Cell*. 141(4):717–27
- 2 Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. 1997. Oncogenic
- 3 ras provokes premature cell senescence associated with accumulation of
- 4 p53 and p16INK4a. *Cell*. 88(5):593–602
- 5 Shay JW, Pereira-Smith OM, Wright WE. 1991. A role for both RB and p53 in
- 6 the regulation of human cellular senescence. *Experimental Cell Research*.
- 7 196(1):33–39
- 8 Shay JW, Wright WE. 2000. *Hayflick, His Limit, and Cellular Ageing.*, Vol. 1
- 9 Shay JW, Wright WE. 2011. Role of telomeres and telomerase in cancer.
- 10 *Semin. Cancer Biol.* 21(6):349–53
- 11 Stanton SE, Adams S, Disis ML. 2016. Variation in the Incidence and
- 12 Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes:
- 13 A Systematic Review. *JAMA Oncol.* 2(10):1354–60
- 14 Storer M, Mas A, Robert-Moreno A, Pecoraro M, Ortells MC, et al. 2013.
- 15 Senescence Is a Developmental Mechanism that Contributes to
- 16 Embryonic Growth and Patterning. *Cell*
- 17 Takai H, Smogorzewska A, de Lange T. 2003. DNA damage foci at
- 18 dysfunctional telomeres. *Current Biology*. 13(17):1549–56
- 19 Tasdemir N, Banito A, Roe J-S, Alonso-Curbelo D, Camiolo M, et al. 2016.
- 20 BRD4 Connects Enhancer Remodeling to Senescence Immune
- 21 Surveillance. *Cancer Discov.* 6(6):612–29
- 22 Toso A, Revandkar A, Di Mitri D, Guccini I, Proietti M, et al. 2014. Enhancing
- 23 chemotherapy efficacy in pten-deficient prostate tumors by activating the
- 24 senescence-associated antitumor immunity. *Cell Rep.* 9(1):75–89
- 25 Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, et al. 2012. IDH1 mutation
- 26 is sufficient to establish the glioma hypermethylator phenotype. *Nature*.
- 27 483(7390):479–83
- 28 Turner NC, Ro J, André F, Loi S, Verma S, et al. 2015. Palbociclib in
- 29 Hormone-Receptor-Positive Advanced Breast Cancer. *N. Engl. J. Med.*
- 30 373(3):209–19
- 31 van Steensel B, Smogorzewska A, de Lange T. 1998. TRF2 protects human
- 32 telomeres from end-to-end fusions. *Cell*. 92(3):401–13
- 33 Vizioli MG, Possik PA, Tarantino E, Meissl K, Borrello MG, et al. 2011.
- 34 Evidence of oncogene-induced senescence in thyroid carcinogenesis.
- 35 *Endocrine Related Cancer*. 18(6):743–57
- 36 Wajapeyee N, Serra RW, Zhu X, Mahalingam M, Green MR. 2008. Oncogenic
- 37 BRAF induces senescence and apoptosis through pathways mediated by
- 38 the secreted protein IGFBP7. *Cell*. 132(3):363–74
- 39 Wajapeyee N, Serra RW, Zhu X, Mahalingam M, Green MR. 2010. Role for
- 40 IGFBP7 in senescence induction by BRAF. *Cell*. 141(5):746–47
- 41 Webster MR, Kugel CH, Weeraratna AT. 2015. The Wnts of change: How
- 42 Wnts regulate phenotype switching in melanoma. *Biochim. Biophys. Acta*.
- 43 1856(2):244–51
- 44 Wu C-H, van Riggelen J, Yetil A, Fan AC, Bachireddy P, Felsher DW. 2007.
- 45 Cellular senescence is an important mechanism of tumor regression upon
- 46 c-Myc inactivation. *Proc. Natl. Acad. Sci. U.S.A.* 104(32):13028–33
- 47 Xue W, Zender L, Miething C, Dickins RA, Hernando E, et al. 2007.
- 48 Senescence and tumour clearance is triggered by p53 restoration in
- 49 murine liver carcinomas. *Nature*. 445(7128):656–60
- 50 Yamakoshi K, Takahashi A, Hirota F, Nakayama R, Ishimaru N, et al. 2009.

- 1 Real-time in vivo imaging of p16Ink4a reveals cross talk with p53. *The*
2 *Journal of Cell Biology*. 186(3):393–407
- 3 Yevsa T, Kang T-W, Zender L. 2012. Immune surveillance of pre-cancerous
4 senescent hepatocytes limits hepatocellular carcinoma development.
5 *Oncoimmunology*. 1(3):398–99
- 6 Yosef R, Pilpel N, Tokarsky-Amiel R, Biran A, Ovadya Y, et al. 2016. Directed
7 elimination of senescent cells by inhibition of BCL-W and BCL-XL. *Nat*
8 *Commun*. 7:11190
- 9 Yoshida A, Lee EK, Diehl JA. 2016. Induction of Therapeutic Senescence in
10 Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6.
11 *Cancer Research*. 76(10):2990–3002
- 12 Yoshimoto S, Loo TM, Atarashi K, Kanda H, Sato S, et al. 2013. Obesity-
13 induced gut microbial metabolite promotes liver cancer through
14 senescence secretome. *Nature*. 499(7456):97–101
- 15 Young ARJ, Narita M, Ferreira M, Kirschner K, Sadaie M, et al. 2009.
16 Autophagy mediates the mitotic senescence transition. *Genes &*
17 *Development*. 23(7):798–803
- 18 Zheng L, Cardaci S, Jerby L, MacKenzie ED, Sciacovelli M, et al. 2015.
19 Fumarate induces redox-dependent senescence by modifying glutathione
20 metabolism. *Nat Commun*. 6:6001
- 21 Zhu J, Woods D, McMahon M, Bishop JM. 1998. Senescence of human
22 fibroblasts induced by oncogenic Raf. *Genes & Development*.
23 12(19):2997–3007
- 24 Zhu Y, Tchkonja T, Pirtskhalava T, Gower AC, Ding H, et al. 2015. The
25 Achilles' heel of senescent cells: from transcriptome to senolytic drugs.
26 *Aging Cell*. 14(4):644–58
- 27 Zhuang D, Mannava S, Grachtchouk V, Tang W-H, Patil S, et al. 2008. C-
28 MYC overexpression is required for continuous suppression of oncogene-
29 induced senescence in melanoma cells. *Nature Publishing Group*.
30 27(52):6623–34
- 31
- 32
- 33
- 34
- 35

1 **Sidebars:**

2 **CHRONIC P53 DATABASE**

3 P53 is constantly produced and degraded through the MDM2-mediated
4 proteasomal system (Kruse & Gu 2009). MDM2 is a canonical transcriptional
5 target of p53, forming a strong negative feedback loop. Thus, p53 is rapidly
6 but transiently stabilized upon DNA damage (herein we call this 'acute p53').
7 However, it was recently shown that comparable levels of p53 accumulate on
8 chromatin in senescent cells in culture ('chronic p53'). Importantly, it has been
9 suggested from in vivo genetic models that it is the persistent activation of
10 p53, rather than the acute p53 response that is more important for the tumor
11 suppressive activity of p53 (Brady et al. 2011, Christophorou et al. 2006). Yet
12 genome-wide mapping of p53 binding sites had been conducted almost
13 exclusively in acute p53 conditions. However, chronic p53-specific targets
14 were recently evaluated through integrating p53 ChIP-seq and transcriptomic
15 datasets, revealing more abundant and distinct p53 targets in the context of
16 OIS compared to acute DDR (Kirschner et al. 2015). Examples of knowledge-
17 based pathway models of chromatin p53 can be found at [http://australian-
18 systemsbiology.org/tp53](http://australian-systemsbiology.org/tp53) (Kirschner et al. 2015). This resource may represent
19 many tumor-associated p53-targets, which have previously been poorly
20 recognized.

21

22 **P16 REGULATION IN SENESCENCE**

23 p16 is an inhibitor of cyclin dependent kinase (CDK4/6)-dependent
24 phosphorylation of RB, thus blocking G1/S cell cycle transition, and the p16-

1 CDK-RB axis is often inactivated in cancer (Gil & Peters 2006). Senescence
2 is typically defined by combination of multiple senescence features in addition
3 to long-term cell cycle exit. This is because of the lack of single definitive
4 markers for senescence (Salama et al. 2014). However, p16 upregulation is
5 probably one of the most specific features of senescence. p16/RB is also
6 functionally important for senescence: for example, ectopic expression of p16
7 is sufficient to induce senescence and loss of p16/RB leads to bypass of
8 senescence. Thus, p16 is a very useful senescence reporter both in culture
9 and tissues. *p16* transcription is, at least in part, regulated by ETS
10 transcription factors (TFs), but the entire regulatory TF network remains
11 unclear. *p16* expression is also under complex regulation, involving polycomb,
12 non-coding RNAs, and high-order chromatin structure (LaPak & Burd 2014).
13 Nevertheless, the *p16* promoter or its relatively small parts have been
14 successfully used to not only faithfully report *p16* expression and senescence
15 induction, but also induce cell death specifically in *p16*-expressing senescent
16 cells in vivo (Baker et al. 2011, Burd et al. 2013, Demaria et al. 2017,
17 Yamakoshi et al. 2009).

18

19 **SASP REGULATION**

20 SASP regulation is best-studied for its inflammatory components. Critical to
21 SASP expression is a pDDR, dependent on ATM and CHK2, but not on p53
22 (Coppé et al. 2008, Rodier et al. 2009). Indeed, p53 plays an inhibitory role in
23 the SASP (Rodier et al. 2009). Transcriptionally, two transcription factors
24 (TFs), RelA and C/EBP β , cooperatively induce 'proximal' inflammatory SASP

1 components, such as IL1 and IL6, which in turn activate these TFs, forming
2 an amplifying loop (Acosta et al. 2008). Thus, blocking these cytokines
3 collapses the SASP network (Acosta et al. 2013, Kuilman et al. 2008, Orjalo
4 et al. 2009). SASP factors, including these cytokines are also under
5 epigenetic regulation, where the chromatin ‘reader’ BRD4 (Tasdemir et al.
6 2016) and chromatin architectural protein HMGB2 positively regulate the
7 SASP (Aird et al. 2016). Several other factors, including post-transcriptional
8 mechanisms, are involved in the cytokine-TFs loop: p38MAPK activation
9 induces the SASP by activating NFkB in a DDR-independent manner (Freund
10 et al. 2011); DDR can activate NFkB by inhibiting ‘selective’ autophagy-
11 degradation of GATA4, which positively regulates IL1a and TRAF3IP2, both
12 NFkB activators (Kang et al. 2015); NOTCH1 inhibits the inflammatory SASP
13 through blocking the C/EBP β activity (Hoare et al. 2016); and mTOR
14 facilitates IL1a translation (Laberge et al. 2015). mTOR also promotes the
15 SASP through stabilization of SASP transcripts (Herranz et al. 2015) or
16 through forming mTOR-('global') autophagy spatial coupling compartment
17 (TASCC) (Narita et al. 2011, Young et al. 2009), although the relationship
18 between the TASCC and the other mTOR-mediated mechanisms is unclear.

19

20 **FIGURE LEGENDS**

21 **Figure 1.** Features of cellular senescence. **a)** The classical view of the
22 senescence pathway. Premature senescence develops as a consequence of
23 a diverse range of stressors, such as ionising radiation, unrestricted oncogene
24 activation or anti-cancer therapies. The cell-cycle arrest of senescence is
25 underpinned by the p53 / p21 pathway and p16 / RB pathway, which co-

1 operatively contribute to senescence establishment and maintenance. **b-c)** A
2 current view of the senescence network involving both autonomous (**b**) and
3 non-autonomous (**c**) features of senescence. Multiple effector mechanisms
4 contribute to the autonomous senescence phenotype including the DNA-
5 damage response (DDR) and autocrine reinforcement through the
6 senescence-associated secretory phenotype (SASP). Oncogene-induced
7 senescence is often accompanied by senescence-associated heterochromatic
8 foci (SAHF) and negative feedback loops repressing activity of the RAS /
9 MAPK / PI3K pathways. **c)** Senescence is associated with profound non-
10 autonomous effects upon multiple players within the microenvironment. Either
11 through SASP-paracrine signaling or cell-contact-dependent juxtacrine
12 signaling, senescent cells are able to promote plasticity, modulate immunity
13 (typically inflammatory, but can also be immunosuppressive), fibrosis
14 (typically fibrotic, but can also be fibrolytic), orchestrate tissue repair, drive
15 angiogenesis and, if persistent, drive chronic inflammation. Dependent on the
16 context of the signal-receiving cell, these non-autonomous effects can be
17 tumour suppressive or pro-oncogenic. Dotted lines represent remote activities
18 through secretory factors. 'No arrow head' lines indicate the effect can be
19 either promoting or suppressing.

20

21 **Figure 2.** Senescence and the Hallmarks of Cancer. Recent work has
22 highlighted the diverse range of autonomous and non-autonomous features of
23 senescence in various models. Some of these features are tumour
24 suppressive, consistent with the previous view of senescence as a tumour

- 1 suppressor mechanism, but other features serve to promote development and
- 2 progression of cancer. We summarise these features here in this pseudo-
- 3 heatmap and link them to the hallmarks of cancer in a simplified manner.




Figure 1. Features of cellular senescence. **a)** The classical view of the senescence pathway. Premature senescence develops as a consequence of a diverse range of stressors, such as ionising radiation, unrestricted oncogene activation or anti-cancer therapies. The cell-cycle arrest of senescence is underpinned by the p53 / p21 pathway and p16 / RB pathway, which co-operatively contribute to senescence establishment and maintenance. **b-c)** A current view of the senescence network involving both autonomous (**b**) and non-autonomous (**c**) features of senescence. Multiple effector mechanisms contribute to the autonomous senescence phenotype including the DNA-damage response (DDR) and autocrine reinforcement through the senescence-associated secretory phenotype (SASP). Oncogene-induced senescence is often accompanied by senescence-associated heterochromatic foci (SAHF) and negative feedback loops repressing activity of the RAS / MAPK / PI3K pathways. **c)** Senescence is associated with profound non-autonomous effects upon multiple players within the microenvironment. Either through SASP-paracrine signaling or cell-contact-dependent juxtacrine signaling, senescent cells are able to promote plasticity, modulate immunity (typically inflammatory, but can also be immunosuppressive), fibrosis (typically fibrotic, but can also be fibrolytic), orchestrate tissue repair, drive angiogenesis and, if persistent, drive chronic inflammation. Dependent on the context of the signal-receiving cell, these non-autonomous effects can be tumour suppressive or pro-oncogenic. Dotted lines represent remote activities through secretory factors. ‘No arrow head’ lines indicate the effect can be either promoting or suppressing.




Figure 2. Senescence and the Hallmarks of Cancer. Recent work has highlighted the diverse range of autonomous and non-autonomous features of senescence in various models. Some of these features are tumour suppressive, consistent with the previous view of senescence as a tumour suppressor mechanism, but other features serve to promote development and progression of cancer. We summarise these features here in this pseudo-heatmap and link them to the hallmarks of cancer in a simplified manner.